News | January 15, 2009

RT Delayed too Long after Breast Surgery Adversely Affects Outcomes

January 15, 2009 - There is no survival disadvantage to waiting up to 20 weeks to start radiation therapy (RT) after breast-conserving surgery (BCS), but delaying more than that does adversely affect outcomes, according to results from a large study published in the January 2009 issue of Journal of Clinical Oncology (J Clin Oncol, 2009 Jan 1, IA Olivotto, et al).

"To date, the optimal, maximally acceptable delay time to begin RT after BCS has not been clearly defined," noted Lee Schwartzberg, M.D., Ph.D., editor-in-chief of OncologySTAT.

Dr. Schwartzberg noted that "[t]his prospectively evaluated, large, population-based study from British Columbia determined that initiation of external-beam RT up to 20 weeks after BCS, in the absence of adjuvant chemotherapy, was associated with similar outcome to earlier initiation. Delay beyond 5 months significantly compromised both the local-regional failure rate (10 percent vs 5.6 percent) and breast cancer–specific survival.

He added, "Left unanswered is how the interspersion of adjuvant systemic chemotherapy, typically given after BCS and before RT, would affect these results."

For more information: www.oncologystat.com

Related Content

Proton Therapy Lowers Risk of Side Effects Compared to Conventional Radiation
News | Proton Therapy | May 23, 2019
Cancer patients getting proton therapy instead of traditional photon radiation are at a significantly lower risk of...
Henry Ford Hospital's ViewRay MRIdian linear accelerator system allows real-time MRI-guided radiotherapy. Shown is the support staff for this system. In the center of the photo is Benjamin Movsas, M.D., chair of radiation oncology at Henry Ford Cancer Institute. Second from the right is Carrie Glide-Hurst, Ph.D., director of translational research, radiation oncology.

Henry Ford Hospital's ViewRay MRIdian linear accelerator system allows real-time MRI-guided radiotherapy. Shown is the support staff for this system. In the center of the photo is Benjamin Movsas, M.D., chair of radiation oncology at Henry Ford Cancer Institute. Second from the right is Carri Glide-Hurst, Ph.D., director of translational research, radiation oncology.

Feature | Henry Ford Hospital | May 21, 2019 | Dave Fornell, Editor
Henry Ford Hospital thought leaders regularly speak at the radiation oncology and radiology conferences about new res
Varian Acquiring Cancer Treatment Services International
News | Radiation Therapy | May 21, 2019
Varian Medical Systems announced it has entered into a definitive agreement to acquire India’s Cancer Treatment...
Videos | Radiation Therapy | May 21, 2019
This is a walk through of the ViewRay MRIdian MRI-guided radiotherapy system installed at ...
Partial Breast Irradiation Effective, Convenient Treatment Option for Low-Risk Breast Cancer
News | Radiation Therapy | May 20, 2019
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast...
New Method Improves Ability to Measure and Maximize Radiation Therapy Dose
News | Radiation Therapy | May 14, 2019
Delivering just the right dose of radiation for cancer patients is a delicate balance in their treatment regime....
Sponsored Content | Videos | Radiation Oncology | May 13, 2019
At ASTRO 2018, Accuray showcased new patient-fi
Radiotherapy After Chemo May Improve Survival in Advanced Hodgkin's Lymphoma Patients
News | Radiation Therapy | May 10, 2019
Patients with advanced Hodgkin's lymphoma who have large tumors at the time of diagnosis may benefit from radiotherapy...
IBA Partnering to Develop Advanced Digital Proton Therapy Technologies in Belgium
News | Proton Therapy | May 10, 2019
IBA (Ion Beam Applications SA) announced a research agreement with Skandionkliniken, Université Catholique de Louvain...